Sphingosine-1-phosphate signalling as a therapeutic target for patients with abnormal glucose metabolism and ischaemic heart disease

Journal of Cardiovascular Medicine

Volumn 15, Issue 7, 2014, Pages 517-524

  Egom, Emmanuel E ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

abnormal glucose metabolism; ischaemic heart disease; sphingosine 1 phosphate

Indexed keywords

INSULIN; SPHINGOSINE 1 PHOSPHATE; GLUCOSE BLOOD LEVEL; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

CARDIAC PATIENT; CARDIOVASCULAR EFFECT; DISORDERS OF CARBOHYDRATE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEART MUSCLE ISCHEMIA; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; LYSOPHOSPHOLIPIDS; MYOCARDIAL ISCHEMIA; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84902550703     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283639755     Document Type: Review

References (76)

1. Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25:1880-1890.
2. Ford ES, Zhao G, Li C. Prediabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010; 55:1310-1317.
3. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24:1614-1619.
4. Amato L, Paolisso G, Cacciatore F, et al. Congestive heart failure predicts the development of noninsulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 1997; 23:213-218.
5. Goode KM, John J, Rigby AS, et al. Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart 2009; 95:917-923.
6. Domanski M, Krause-Steinrauf H, Deedwania P, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2003; 42:914-922.
7. Thrainsdottir IS, Aspelund T, Hardarson T, et al. Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study. Eur J Cardiovasc Prev Rehabil 2005; 12:465-471.
8. Egom EE, Mamas MA, Clark AL. The potential role of sphingolipid-mediated cell signaling in the interaction between hyperglycemia, acute myocardial infarction and heart failure. Expert Opin Ther Targets 2012; 16:791-800.
9. Bruce CR, Risis S, Babb JR, et al. Overexpression of sphingosine kinase 1 prevents ceramide accumulation and ameliorates muscle insulin resistance in high-fat diet-fed mice. Diabetes 2012; 61:3148-3155.
10. Chavez JA, Summers SA. A ceramide-centric view of insulin resistance. Cell Metab 2012; 15:585-594.
11. Egom EE, Mohamed TM, Mamas MA, et al. Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. Am J Physiol Heart Circ Physiol 2011; 301:H1487-H1495.
12. Egom EE, Mamas M, Chacko S, et al. Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injury. Front Physiol 2013; 4:130.
13. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359:2140-2144.
14. Mah E, Bruno RS. Postprandial hyperglycemia on vascular endothelial function: mechanisms and consequences. Nutr Res 2012; 32:727-740.
15. Ishihara M. Acute hyperglycemia in patients with acute myocardial infarction. Circ J 2012; 76:563-571.
16. Ceriello A. Acute hyperglycaemia and oxidative stress generation. Diabet Med 1997; 14 (Suppl 3):S45-S49.
17. Ceriello A, Giacomello R, Stel G, et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 1995; 44:924-928.
18. Van Brocklyn JR, Williams JB. The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: oxidative stress and the seesaw of cell survival and death. Comp Biochem Physiol B Biochem Mol Biol 2012; 163:26-36.
19. Maceyka M, Milstien S, Spiegel S. Shooting the messenger: oxidative stress regulates sphingosine-1-phosphate. Circ Res 2007; 100:7-9.
20. Pchejetski D, Kunduzova O, Dayon A, et al. Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-Associated cardiac cell apoptosis. Circ Res 2007; 100:41-49.
21. Egom EE, Ke Y, Solaro RJ, Lei M. Cardioprotection in ischemia/reperfusion injury: spotlight on sphingosine-1-phosphate and bradykinin signalling. Prog Biophys Mol Biol 2010; 103:142-147.
22. Carr JM, Mahalingam S, Bonder CS, Pitson SM. Sphingosine kinase 1 in viral infections. Rev Med Virol 2013; 23:73-84.
23. Machesky NJ, Zhang G, Raghavan B, et al. Human cytomegalovirus regulates bioactive sphingolipids. J Biol Chem 2008; 283:26148-26160.
24. Pyne NJ, Tonelli F, Lim KG, Long JS, Edwards J, Pyne S. Sphingosine 1-phosphate signalling in cancer. Biochem Soc Trans 2012; 40:94-100.
25. Watson C, Long JS, Orange C, et al. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol 2010; 177:2205-2215.
26. Egom EE. A therapeutic approach to hyperglycaemia in the setting of acute myocardial infarction: spotlight on glucagon-like peptide 1. Ther Adv Cardiovasc Dis 2012; 6:213-219.
27. Hammad SM, Pierce JS, Soodavar F, et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J Lipid Res 2010; 51:3074-3087.
28. Egom EE, Mamas MA, Soran H. HDL quality or cholesterol cargo: what really matters-spotlight on sphingosine-1-phosphate-rich HDL. Curr Opin Lipidol 2013. [Epub ahead of print]
29. Karliner JS. Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim Biophys Acta 2013; 1831:203-212.
30. Ulrych T, Bohm A, Polzin A, et al. Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost 2011; 9:790-798.
31. Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007; 316:295-298.
32. Hisano Y, Nishi T, Kawahara A. The functional roles of S1P in immunity. J Biochem 2012; 152:305-311.
33. Windh RT, Lee MJ, Hla T, An S, Barr AJ, Manning DR. Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the G(i), G(q), and G(12) families of heterotrimeric G proteins. J Biol Chem 1999; 274:27351-27358.
34. Okamoto H, Takuwa N, Gonda K, et al. EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2\+ mobilization, Ras-mitogenactivated protein kinase activation, and adenylate cyclase inhibition. J Biol Chem 1998; 273:27104-27110.
35. Lee MJ, Thangada S, Claffey KP, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999; 99:301-312.
36. Lee MJ, Van Brocklyn JR, Thangada S, et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 1998; 279:1552-1555.
37. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 2000; 349:385-402.
38. Tao R, Hoover HE, Zhang J, Honbo N, Alano CC, Karliner JS. Cardiomyocyte S1P1 receptor-mediated extracellular signal-related kinase signaling and desensitization. J Cardiovasc Pharmacol 2009; 53:486-494.
39. Zhang J, Honbo N, Goetzl EJ, Chatterjee K, Karliner JS, Gray MO. Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol 2007; 293:H3150-H3158.
40. Karliner JS. Mechanisms of cardioprotection by lysophospholipids. J Cell Biochem 2004; 92:1095-1103.
41. Nakajima N, Cavalli AL, Biral D, et al. Expression and characterization of Edg-1 receptors in rat cardiomyocytes: calcium deregulation in response to sphingosine 1-phosphate. Eur J Biochem 2000; 267:5679-5686.
42. Ohmori T, Yatomi Y, Osada M, et al. Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc Res 2003; 58:170-177.
43. Robert P, Tsui P, Laville MP, et al. EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J Mol Cell Cardiol 2001; 33:1589-1606.
44. Sanna MG, Liao J, Jo E, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004; 279:13839-13848.
45. Curry FR, Adamson RH. Tonic regulation of vascular permeability. Acta Physiol 2013; 207:628-649.
46. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427:355-360.
47. Diviani D, Lattion AL, Cotecchia S. Characterization of the phosphorylation sites involved in G protein-coupled receptor kinase-And protein kinase Cmediated desensitization of the alpha1B-Adrenergic receptor. J Biol Chem 1997; 272:28712-28719.
48. Freedman NJ, Liggett SB, Drachman DE, Pei G, Caron MG, Lefkowitz RJ. Phosphorylation and desensitization of the human beta 1-Adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase. J Biol Chem 1995; 270:17953-17961.
49. Pitcher J, Lohse MJ, Codina J, Caron MG, Lefkowitz RJ. Desensitization of the isolated beta 2-Adrenergic receptor by beta-Adrenergic receptor kinase, cAMP-dependent protein kinase, and protein kinase C occurs via distinct molecular mechanisms. Biochemistry 1992; 31:3193-3197.
50. Castillo-Badillo JA, Molina-Munoz T, Romero-Avila MT, et al. Sphingosine 1-phosphate-mediated alpha1B-Adrenoceptor desensitization and phosphorylation. Direct and paracrine/autocrine actions. Biochim Biophys Acta 2012; 1823:245-254.
51. Garcia-Sainz JA, Villalobos-Molina R. The elusive alpha(1D)-Adrenoceptor: molecular and cellular characteristics and integrative roles. Eur J Pharmacol 2004; 500:113-120.
52. Takata Y, Kato H. Adrenoceptors in SHR: alterations in binding characteristics and intracellular signal transduction pathways. Life Sci 1996; 58:91-106.
53. Deutschman DH, Carstens JS, Klepper RL, et al. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J 2003; 146:62-68.
54. Sattler KJ, Elbasan S, Keul P, et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol 2010; 105:821-832.
55. Knapp M, Baranowski M, Czarnowski D, et al. Plasma sphingosine-1- phosphate concentration is reduced in patients with myocardial infarction. Med Sci Monit 2009; 15:CR490-CR493.
56. Doehner W, Bunck AC, Rauchhaus M, et al. Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur Heart J 2007; 28:821-828.
57. Abstracts of the 23rd Great Wall International Congress of Cardiology, Asia Pacific Heart Congress 2012. October 11-14, 2012. Beijing, China. Heart 2012; 98 Suppl 2:E1-319.
58. Egom EE, Ke Y, Musa H, et al. FTY720 prevents ischemia/reperfusion injury-Associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J Mol Cell Cardiol 2010; 48:406-414.
59. Ma MM, Chen JL, Wang GG, et al. Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice. Diabetologia 2007; 50:891-900.
60. Rapizzi E, Taddei ML, Fiaschi T, Donati C, Bruni P, Chiarugi P. Sphingosine 1-phosphate increases glucose uptake through trans-Activation of insulin receptor. Cell Mol Life Sci 2009; 66:3207-3218.
61. Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. PPARs and the cardiovascular system. Antioxid Redox Signal 2009; 11:1415-1452.
62. Baranowski M, Blachnio A, Zabielski P, Gorski J. PPARalpha agonist induces the accumulation of ceramide in the heart of rats fed high-fat diet. J Physiol Pharmacol 2007; 58:57-72.
63. Son NH, Park TS, Yamashita H, et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest 2007; 117:2791-2801.
64. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289.
65. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471.
66. Park TS, Hu Y, Noh HL, et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008; 49:2101-2112.
67. Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007; 5:167-179.
68. Straczkowski M, Kowalska I, Nikolajuk A, et al. Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes 2004; 53:1215-1221.
69. Baranowski M, Zabielski P, Blachnio A, Gorski J. Effect of exercise duration on ceramide metabolism in the rat heart. Acta Physiol 2008; 192:519-529.
70. Oyama O, Sugimoto N, Qi X, et al. The lysophospholipid mediator sphingosine-1-phosphate promotes angiogenesis in vivo in ischaemic hindlimbs of mice. Cardiovasc Res 2008; 78:301-307.
71. Liu Y, Wada R, Yamashita T, et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 2000; 106:951-961.
72. Inoki I, Takuwa N, Sugimoto N, et al. Negative regulation of endothelial morphogenesis and angiogenesis by S1P2 receptor. Biochem Biophys Res Commun 2006; 346:293-300.
73. McVerry BJ, Garcia JG. In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. Cell Signal 2005; 17:131-139.
74. Singleton PA, Dudek SM, Ma SF, Garcia JG. Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family. J Biol Chem 2006; 281:34381-34393.
75. Lynch KR. Building a better sphingosine kinase-1 inhibitor. Biochem J 2012; 444:e1-e2.
76. Schnute ME, McReynolds MD, Kasten T, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J 2012; 444:79-88.